Therapeutic Solutions files Patent on Methods of Re-Activating Dormant Memory Cells with Anticancer Activity

OCEANSIDE, CA --(Marketwired - June 05, 2017) - Therapeutic Solutions International, Inc., (OTC PINK: TSOI) announced today the filing of a new patent for a biologic product called "MemoryMune".

The patent describes methods, protocols and compositions of matter useful for stimulation of anticancer immune responses. In one embodiment of the invention, culturing of buffy coat cells is performed in an environment resembling non-physiological conditions. Buffy coat derived products are subsequently harvested, concentrated, and added to a culture of monocytes and lymphocytes. Conditioned media from this second culture is subsequently utilized as an injectable solution for stimulation of anticancer immunity.

MemoryMune therefore is a product derived from a two-step culture process of donor blood cells. MemoryMune is being developed with the purpose of reawakening dormant immune memory cells by mimicking a process called "homeostatic immune expansion". It is known that many cancer patients possess memory T cells that enter the tumor, however, once inside the tumor these cells are inactivated. MemoryMune contains a unique combination of growth factors specific for immune system cells called "cytokines".

"There are numerous ways of activating the immune system to kill cancer. Although in many cases therapies show some level of efficacy, in the majority of situations tumors come back, in part because of inability of the immune system to form and maintain proper memory T cells," said Timothy Dixon, President and CEO of Therapeutic Solutions International. "Based on our early data, it appears that MemoryMune may be capable of overcoming memory cell exhaustion, thus providing cancer patients a fighting chance of inhibiting tumor recurrence."

"In contrast to conventional T cells, memory T cells have a reduced need for 'co-stimulation', meaning that they are primed and ready to induce immune response against cancer cells when cancer re-occurs. Unfortunately in cancer patients, 'blocking factors' are generated by tumors which inhibit function of memory T cells. The cytokines in MemoryMune, such as interleukin-7 and interleukin-15 have been previously shown to re-activate memory cells. We believe MemoryMune is a means of delivering cytokines such as these in a physiological manner," said Dr. Thomas Ichim, Director of Therapeutic Solutions International.

About Therapeutic Solutions International, Inc.
The Company's corporate website is www.therapeuticsolutionsint.com. Our new products can be viewed on www.projuvenol.com and products can be ordered at www.youcanordernow.com.

These Supplement products have not been evaluated by the United States Food and Drug Administration. These products are not intended to diagnose, treat, cure or prevent any diseases.

Safe Harbor Statement
This release contains forward-looking statements that are based upon current expectations or beliefs, as well as a number of assumptions about future events. Although we believe that the expectations reflected in the forward-looking statements and the assumptions upon which they are based are reasonable, we can give no assurance that such expectations and assumptions will prove to have been correct. Forward-looking statements are generally identifiable by the use of words like "may," "will," "should," "could," "expect," "anticipate," "estimate," "believe," "intend," or "project" or the negative of these words or other variations on these words or comparable terminology. The reader is cautioned not to put undue reliance on these forward-looking statements, as these statements are subject to numerous risk factors as set forth in our SEC filings. To the extent that statements in this press release are not strictly historical, including statements as to product launch timing, revenue projections, business strategy, outlook, objectives, future milestones, plans, intentions, goals, future collaboration agreements, or otherwise as to future events, such statements are forward-looking, and are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. The forward-looking statements contained in this release are subject to certain risks and uncertainties that could cause actual results to differ materially from the statements made.